Noxopharm Limited (NOXOF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -534.81 Thousand AUD | -109.13% |
| 2023 | 5.85 Million AUD | 13.32% |
| 2022 | 5.16 Million AUD | -3.36% |
| 2021 | 5.34 Million AUD | -33.51% |
| 2020 | 8.04 Million AUD | 117.99% |
| 2019 | 3.68 Million AUD | 330.08% |
| 2018 | 857.64 Thousand AUD | 792.98% |
| 2017 | 96.04 Thousand AUD | 2970.38% |
| 2016 | -3346.00 AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -147.87 Thousand AUD | -124.44% |
| 2024 FY | -1743.00 AUD | -100.03% |
| 2024 Q1 | -119.53 Thousand AUD | -109.05% |
| 2024 Q2 | 605.1 Thousand AUD | 606.24% |
| 2024 Q4 | -147.87 Thousand AUD | 0.0% |
| 2023 FY | 5.85 Million AUD | 13.32% |
| 2023 Q3 | -1.09 Million AUD | -171.51% |
| 2023 Q4 | 1.32 Million AUD | 220.8% |
| 2023 Q2 | 1.52 Million AUD | 224.89% |
| 2023 Q1 | -1.22 Million AUD | -172.45% |
| 2022 Q2 | 762.63 Thousand AUD | 216.88% |
| 2022 Q4 | 1.69 Million AUD | 423.86% |
| 2022 FY | 5.16 Million AUD | -3.36% |
| 2022 Q1 | -652.49 Thousand AUD | -132.7% |
| 2022 Q3 | -521.88 Thousand AUD | -168.43% |
| 2021 Q2 | 546.76 Thousand AUD | 164.64% |
| 2021 FY | 5.34 Million AUD | -33.51% |
| 2021 Q3 | -2.63 Million AUD | -581.1% |
| 2021 Q4 | 1.99 Million AUD | 175.87% |
| 2021 Q1 | -845.88 Thousand AUD | -139.69% |
| 2020 Q4 | 2.13 Million AUD | 965.25% |
| 2020 FY | 8.04 Million AUD | 117.99% |
| 2020 Q2 | 1.76 Million AUD | 1583.68% |
| 2020 Q1 | 105.02 Thousand AUD | -50.51% |
| 2020 Q3 | 200.09 Thousand AUD | -88.68% |
| 2019 Q1 | 1.63 Million AUD | 5249.97% |
| 2019 Q4 | 212.2 Thousand AUD | -12.74% |
| 2019 Q3 | 243.16 Thousand AUD | -85.1% |
| 2019 Q2 | 1.63 Million AUD | -0.0% |
| 2019 FY | 3.68 Million AUD | 330.08% |
| 2018 Q4 | 30.5 Thousand AUD | 0.0% |
| 2018 FY | 857.64 Thousand AUD | 792.98% |
| 2018 Q1 | 427.75 Thousand AUD | 577.37% |
| 2018 Q2 | 427.75 Thousand AUD | 0.0% |
| 2018 Q3 | 30.5 Thousand AUD | -92.87% |
| 2017 FY | 96.04 Thousand AUD | 2970.38% |
| 2017 Q1 | - AUD | 0.0% |
| 2017 Q4 | 63.15 Thousand AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 Q3 | 63.15 Thousand AUD | 0.0% |
| 2016 FY | -3346.00 AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | -6355.172% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 103.566% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 105.461% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 913.673% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 104.569% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.449% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -1466.064% |
| Marizyme, Inc. | 457.7 Thousand USD | 216.847% |
| Genus plc | 178.7 Million USD | 100.299% |
| Pharming Group N.V. | 220.1 Million USD | 100.243% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 959.465% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 230.389% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -4761.918% |
| ContraFect Corporation | -154 Thousand USD | -247.28% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 796.722% |
| IMV Inc. | -962.29 Thousand USD | 44.424% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -38.015% |
| ONE Bio Corp. | 20.12 Million USD | 102.657% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 101.328% |
| Mesoblast Limited | -35.16 Million USD | 98.479% |
| MultiCell Technologies, Inc. | 49.32 USD | 1084469.424% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 101.893% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.131% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 17340.845% |
| Biomind Labs Inc. | -15.42 Thousand USD | -3367.395% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 53.151% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 864.016% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -330.428% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -10699.899% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -969.622% |
| Arch Therapeutics, Inc. | -2439.00 USD | -21827.47% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 480.648% |
| Accustem Sciences Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 1193.683% |
| Q BioMed Inc. | -8988.00 USD | -5850.278% |
| GB Sciences, Inc. | -624.00 USD | -85606.891% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -521.671% |
| CSL Limited | 7.56 Billion USD | 100.007% |
| Agentix Corp. | - USD | Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 101.206% |
| Enzolytics Inc. | 30.7 Thousand USD | 1841.602% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 210.857% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -448.44% |
| argenx SE | 1.1 Billion USD | 100.048% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 97.927% |
| HST Global, Inc. | - USD | Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -257020.673% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -3.946% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| Zenith Capital Corp. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -5938.968% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 186.625% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -537.826% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 154.132% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 105.565% |
| Kadimastem Ltd | -630.13 Thousand USD | 15.128% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 103.467% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -4418.893% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -1008.21% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 402.906% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 402.906% |
| Affymax, Inc. | 1.35 Million USD | 139.407% |
| Mobile Lads Corp. | - USD | Infinity% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 111.606% |
| CytoDyn Inc. | -29 Thousand USD | -1744.176% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 218.836% |
| SYBLEU INC | 11.69 Thousand USD | 4672.597% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -67.386% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -43.381% |
| Neutra Corp. | 14.33 Thousand USD | 3830.806% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -552.209% |
| PureTech Health plc | -1.6 Million USD | 66.637% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 46.585% |
| IXICO plc | 3.27 Million USD | 116.355% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 22.938% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 70.139% |
| CSL Limited | 7.7 Billion USD | 100.007% |
| Cellectis S.A. | 18 Thousand USD | 3071.172% |